Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Valemetostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Daiichi Sankyo’s Ezharmia Receives Japanese Approval For T-Cell Lymphoma
    Daiichi Sankyo’s Ezharmia Receives Japanese Approval For T-Cell Lymphoma

    25 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169939&sid=2

    PHARMABIZ
    25 Jun 2024
    Share Share
    Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy
    Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy

    20 Dec 2022

    // INDIANPHARMAPOST

    https://www.indianpharmapost.com/news/ezharima-launched-in-japan-as-first-dual-ezh1-and-ezh2-inhibitor-therapy-for-leukemialymphoma-13478

    INDIANPHARMAPOST
    20 Dec 2022
    Share Share
    Valemetostat NDA Submitted in Japan for Adult T-Cell Leukemia/Lymphoma
    Valemetostat NDA Submitted in Japan for Adult T-Cell Leukemia/Lymphoma

    28 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211222005563/en

    BUSINESSWIRE
    28 Dec 2021
    Share Share
    Valemetostat Pivotal Data Shows Promising Response Rates in ATL
    Valemetostat Pivotal Data Shows Promising Response Rates in ATL

    11 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211211005008/en

    BUSINESSWIRE
    11 Dec 2021
    Share Share
    Valemetostat Data at EHA Shows Promising Durable Tumor Response
    Valemetostat Data at EHA Shows Promising Durable Tumor Response

    11 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210611005034/en

    BUSINESSWIRE
    11 Jun 2021
    Share Share
    Valemetostat Data at EHA Shows Promising Durable Tumor Response
    Valemetostat Data at EHA Shows Promising Durable Tumor Response

    11 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210611005034/en

    BUSINESSWIRE
    11 Jun 2021
    Share Share